56 results about "OA - Osteoarthrosis" patented technology

The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis. In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, and / or OA progression. Methods and kits are described for using these protein expression profiles in the study and / or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and / or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.

This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed.

The invention belongs to the field of nano-enzyme preparation and biological application, and particularly relates to a preparation method and application of M2 type macrophage membrane coated FeMn diatomic nano-enzyme. The preparation method comprises the following steps: by taking nitrogen-doped carbon (BANT) as a carrier, loading Fe and Mn diatoms, synthesizing a novel nano material FeMnDA / BCNT diatomic nano-enzyme, extracting a macrophage membrane from natural macrophages, and coating the FeMnDA / BCNT nano material with the macrophage membrane to finally form M2 type macrophage membrane coated nano-particles, namely [MM] FeMnDA / BCNT. The [MM] FeMnDA / BCNT nano-enzyme prepared by the invention has good biological safety and simulated SOD and CAT enzyme activity, and the expression of inflammatory factors is reduced by removing excessive ROS (reactive oxygen species) in the cartilage cells induced by H2O2, so that the damage of oxidative stress to the cartilage cells is inhibited. The [MM] FeMnDA / BCNT nano-enzyme is not used for treating OA yet, so that a scientific basis is provided for further application and expansion of the diatomic nano-enzyme, and an effective strategy and a new thought are provided for treating osteoarthritis and chronic diseases related to oxidative stress in the future.

The invention provides application of fibroblast activation protein (Fap) as a target in screening drugs for treating osteoarthritis (OA) or inhibiting cartilage injury or osteophyte generation or synovitis. The invention also provides application of an Fap gene as a target in screening drugs for treating OA or inhibiting cartilage injury or osteophyte generation or synovitis. The invention also provides application of a targeted Fap inhibitor in preparation of drugs for treating OA or inhibiting cartilage injury or osteophyte generation or synovitis. The invention also provides application ofosteolectin (Oln) in preparation of drugs for treating OA or inhibiting cartilage injury or osteophyte generation or synovitis. It is found that Fap is highly expressed in synovial membrane of OA, cartilage injury, osteophyte generation, synovitis and cartilage aggregation protein polysaccharide loss of mouse OA can be relieved by inhibiting Fap through genetics and pharmacology, and both an Fapsmall-molecule inhibitor and an endogenous protein inhibitor Oln can treat the OA.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The invention provides an application of MicroRNA-455-3p as an osteoarthritis treatment target and an application of an exosome for overexpression of MicroRNA-455-3p in preparation of a drug for treating osteoarthritis. According to the invention, the MicroRNA-455-3p is used as an osteoarthritis treatment target, and the exosome vector for overexpression of the MicroRNA-455-3p is constructed to carry out early intervention on osteoarthritis so as to realize the purpose of treating OA.

Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) and determining treatment are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, Apolipoprotein A1, and Apolipoprotein E. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.

The invention belongs to the technical field of biological medicines, and discloses a B cell and cartilage cell senescence targeting osteoarthritis treatment medicine. The invention provides an application of an anti-MIF antibody or an antigen binding fragment thereof as a B cell targeting immunomodulator in osteoarthritis treatment drugs, the anti-MIF antibody or the antigen binding fragment thereof regulates and controls an MIF / HMGB1 / MMP13 signal axis through a neutralization effect with MIF, so that the MIF and B cells are significantly co-localized, expression of HMGB1 in the B cells is promoted, and the osteoarthritis treatment effect is improved. The senescence of B cells is reduced and the B cells are promoted to regulate or repair phenotype transformation so as to destroy chronic inflammatory circulation and diffusion of pathogenic plasma cells, and the expression of MMP13 in joint tissues is reduced so as to maintain the steady state of cartilage tissues; the preparation method has an excellent application prospect in preparation of an OA intra-articular injection drug which realizes rapid anti-inflammatory and long-term cartilage protection effects and can realize a lasting curative effect through low-frequency drug delivery.

The invention relates to the technical field of osteoarthritis drugs, particularly discloses an application of DDX5-K45mRNA in preparation of drugs for treating and / or relieving osteoarthritis, and provides a drug delivery system for targeting chondrocytes at the same time, research finds that when DDX5-K45mRNA is added into the chondrocytes, the drug delivery system can be used for treating and / or relieving osteoarthritis. The medicine can restore DDX5-K45 lactic acid, block NF-kappa B inflammation signals, correct metabolic reprogramming (such as inhibition of abnormal glycolysis), and up-regulate cartilage protection factors such as COL2A1 and the like. The LNP is utilized to efficiently deliver DDX5-K45mRNA to cartilage cells, endogenous lactic acid modification defects are directly supplemented, the cartilage protection function of DDX5 is reconstructed, inflammatory response is inhibited, matrix degradation is reduced, the cartilage steady state is maintained fundamentally, and long-acting and safe OA treatment is achieved.

The invention belongs to the field of biomedicine, and provides application of LDHA as a treatment target of aging-related osteoarthritis. In-vitro cell experiments and animal in-vivo experiments prove that the LDHA inhibitor can inhibit OA progress caused by aging, and targeted inhibition of LDHA in synovial fibroblasts can provide a brand-new treatment strategy for treatment of aging-related osteoarthritis.

The invention relates to an ROS-responsive macrophage-chondrocyte dual-targeting nano-micelle and a preparation method and application thereof, HA capable of targeting and highly expressing CD44 cells is taken as a carrier skeleton, chemical coupling with TK and CUR is carried out in sequence, self-assembly is carried out through intermolecular force to form a stable nano-micelle, and drugs JPH203 and KGN are entrapped at the same time, so that efficient loading and targeting delivery are realized. The HA can be specifically combined with RAW264.7 macrophages and articular cartilage cells for highly expressing a CD44 receptor in an inflammatory state, and is actively delivered in a targeting manner. The ROS response characteristic of TK is utilized, oxidative fracture is carried out in an OA high ROS microenvironment, and micelles are triggered to disintegrate and release drugs accurately. The released JPH203 can inhibit an inflammatory mTOR pathway and effectively resist inflammation, and KGN is beneficial to promoting cartilage cell proliferation and effectively collecting and promoting differentiation of mesenchymal stem cells into cartilage cells, so that in-situ cartilage regeneration is realized, and a more efficient solution with low side effects is provided for osteoarthritis treatment.

Compositions and methods are provided for determining the presence of early-stage osteoarthritis (OA) in an individual by single cell profiling of a blood sample. Through use of machine learning, it is shown that immune cell features associated with OA are present and detectable in the early stages of OA and can be utilized for early detection of the disease.

The invention discloses a pathological microenvironment self-driven precise targeting nano-robot as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing an MOF carrier; (2) preparing MOF-coated ISLamp; a CORM-401 compound, and an organic solvent; (3) preparing apoptotic cell membranes; (4) preparing an FH peptide modified apoptosis cell membrane: coupling the FH peptide with a synthetic sequence of FHKHKSPALSPV with DSPE-PEG-NHS, then mixing with apM, carrying out ultrasonic treatment, and carrying out centrifugal purification to obtain FM; (5) preparing a nano robot: MOF (at) ISLamp; the CORM-401 and the FM membrane protein are mixed, asymmetrically wrapped, extruded to pass through a membrane, and centrifuged to obtain the nano-robot. According to the designed self-driven nano-robot integrating the triple functions of self-driving, precise targeting and collaborative treatment, CORM-401-ROS reaction is used for providing active power to break through a synovial membrane barrier, targeted enrichment of core pathological cells is achieved through an engineered cell membrane, the mitochondrial function is synergistically repaired by means of ISL and CO, OA pathological circulation is blocked, and the targeted enrichment of the core pathological cells is achieved. A brand new technical scheme is provided for treatment of osteoarthritis from symptomatic remission to pathological reversion.

Provided herein are compositions containing dehydrated placental tissue particulates, methods of making the compositions and methods for treating various musculoskeletal disorders and other conditions using such compositions, including osteoarthritis (OA), degenerative disc disease, tendonitis, plantar fasciitis, and pain associated therewith.

The application discloses a pathological microenvironment self-driven precise targeted nanorobot and a preparation method and application thereof, and is prepared according to the following steps: (1) preparing a MOF carrier; (2) preparing a MOF@ISL&CORM-401 compound; (3) preparing an apoptotic cell membrane; (4) preparing an FH peptide modified apoptotic cell membrane: coupling FH peptide with a sequence of FHKHKSPALSPV and DSPE-PEG-NHS, mixing with apM under ultrasonic, centrifugal purification, and obtaining FM; (5) preparing a nanorobot: mixing the MOF@ISL&CORM-401 and the membrane protein of FM, asymmetrically wrapping, extruding through the membrane, and centrifugal to obtain the nanorobot. The self-driven nanorobot with the triple functions of self-driving, precise targeting and synergistic treatment is designed, the CORM-401-ROS reaction is utilized to provide active power to break through the synovial membrane barrier, the engineered cell membrane is utilized to realize the targeted enrichment of core pathological cells, the ISL and CO are utilized to repair the mitochondrial function, and the OA pathological cycle is blocked, so that a novel technical scheme is provided for the treatment of osteoarthritis from the symptomatic relief to the pathological reversal.

The invention discloses application of L-glutamine in treatment of osteoarthritis, and relates to the field of biomedicine. The L-Gln is used for treating a rat OA animal model, and the direct curative effect of the L-Gln on OA is systematically evaluated from the aspects of inflammatory response, extracellular matrix secretion, chondrocyte survival, cartilage regeneration and the like. According to the present invention, the L-Gln is used as an anti-osteoarthritis drug, NKILA gene silencing, TGF-beta receptor blocker and other methods are combined to verify that L-Gln can up-regulate NKILA expression through a TGF-beta 1 pathway so as to inhibit NF-kappa B activation, reduce chondrocyte inflammatory injury and promote extracellular matrix secretion and cartilage repair, the L-Gln can be used as a new, cheap and effective osteoarthritis disease improvement drug, pain caused by diseases of patients can be relieved, the damaged cartilage structure is fundamentally improved, and therefore the progress of the diseases is delayed.

A polypeptide that is active against each of a GIP, a GLP-1, and a glucagon receptor is provided. The polypeptides have structural features that result in each of the receptors having activity and extended action time. Also provided are methods for treating diseases and / or conditions such as obesity, long term weight management, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-associated sleep apnea (OSA), and polycystic ovarian syndrome (PCOS).

The invention belongs to the technical field of biomedicine and particularly relates to application of circular RNA as an osteoarthritis marker. The circular RNA is has_circ_0000423 and has a nucleotide sequence represented by SEQ ID NO: 1. According to the application, researches discover that compared with normal cartilage tissue, hsa_circ_0000423 is of high expression in cartilage tissue of an osteoarthritis sufferer, so that judgment on whether a testee has the high risk of suffering from osteoarthritis or not is contributed through detecting the content of the hsa_circ_0000423, and the significance in clinical auxiliary diagnosis and evaluation on the osteoarthritis is remarkable. Simultaneously, through further researching biological functions of cartilage cells, diagnosis and treatment values of the hsa_circ_0000423 during occurrence and development of OA are discovered, so that a critical theoretical basis and intervention target is provided for diagnosis and treatment on the disease, and thus, the circular RNA has an important potential value and a good application prospect.

The present disclosure refers to novel RNA molecules based on miRNAs which are useful for the treatment of osteoarthritis (OA), by modulating the expression of OA-related genes, as well as combinations and compositions comprising them, and methods related thereto.

Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.

An umbilical cord mesenchymal stem cell and application thereof in treating osteoarthritis. The application discloses a dual-response hydrogel drug delivery system for osteoarthritis treatment and application thereof, and relates to a synergistic design of a bifunctional fusion protein BFP, an epigenetic regulator TSA and a temperature-sensitive-enzyme response hydrogel. The bifunctional protein BFP contains a cartilage induction domain CIP-2 and an anti-inflammatory domain AIP-3, which are connected in series through a rigid connection peptide EAKAK, and can specifically activate the TGF-beta pathway and respond to MMP9 to release the anti-inflammatory fragment. The temperature-sensitive-enzyme dual-response hydrogel is composed of thiolated hyaluronic acid and poloxamer 407, and can rapidly gelate within 3.5±0.5 minutes at 37 DEG C, the gel transition point is 29.2±0.3 DEG C, and the synergistic release of BFP / TSA can be realized in the presence of MMP9, and the 72-hour release rate reaches 86.7%. Experiments prove that the system can make the SOX9 / COL2A1 gene expression of UC-MSCs increase by 6.77 times and 5.9 times respectively, the GAG deposition amount reaches 0.81 OD630, the ICRS score in the rat OA model increases by 267%, and the serum MMP-13 level decreases by 78.3%. Therefore, the technology of the application provides a new direction for the precise treatment of osteoarthritis.

The invention provides an intelligent response nanoprobe for targeted diagnosis and treatment of osteoarthritis and a preparation method of the intelligent response nanoprobe, and belongs to the field of nanomedicine. According to the method, amino cerium oxide is innovatively connected to the surface of mesoporous gadolinium-doped Prussian blue (Gd-HMPB) coated with hyaluronic acid, and an anti-inflammatory drug is packaged into pores of the Gd-HMPB in an SMT (Surface Mount Technology) manner, so that the targeted intelligent response nano probe for diagnosis and treatment of osteoarthritis (OA) is prepared. Under the targeting action of hyaluronic acid, the intelligent response nanoprobe accurately reaches the OA cartilage part, and the inflammation position is accurately judged by virtue of a magnetic resonance imaging technology. In the acidic microenvironment of inflammation, SMT released by the nanoprobe can cooperate with HMPB and CeO2 nanoenzyme to remove ROS and inflammatory factors and promote polarization of macrophages to anti-inflammatory macrophages, so that the effect of remodeling the OA microenvironment is achieved, and a new thought is expected to be provided for clinical precise diagnosis and treatment of OA.

The invention relates to a preparation method and application of alpha2-macroglobulin. The invention finds that the alpha2-macroglobulin can be used for promoting the intercellular effect of cells, and further can be used for preparing medicines for treating osteoarthritis, atherosclerosis, inflammatory aging, tumors, chronic obstructive pulmonary disease, systemic lupus erythematosus and other diseases caused by intercellular function deficiency.

The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and / or cancer including colorectal cancer.The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the specification.

Provided herein are compositions containing dehydrated placental tissue particulates, methods of making the compositions and methods for treating various musculoskeletal disorders and other conditions using such compositions, including osteoarthritis (OA), degenerative disc disease, tendonitis, plantar fasciitis, and pain associated therewith.

Compositions and methods are provided for determining the presence of early-stage osteoarthritis (OA) in an individual by single cell profiling of B cell population(s) in a blood sample. Expansion of CD25hi switched memory B cells is detectable in the early stages of OA and can be utilized for early detection of the disease.

The invention provides application of an active component. The active component is characterized in that the active component is selected from fraxetin or analogues or derivatives thereof; the fraxetin is a compound shown in the following structure. The active component is used for reducing the expression level of serum cartilage conversion and inflammation biomarkers of OA rats and relieving apoptosis, inflammation and matrix catabolism of cartilage cells.